Illumina and QIAGEN Partner to Deliver Sequencing-Based In-Vitro Diagnostic (IVD) Tests
Illumina, Inc. (ILMN)
Last illumina, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
illumina.com/company/investor-information.html
Company Research
Source: Business Wire
Partnership to accelerate the adoption of next-generation sequencing (NGS) in clinical decision-making SAN DIEGO & HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ: ILMN) and QIAGEN N.V. (NYSE: QGEN) (Frankfurt Prime Standard: QIA) today announced a 15-year partnership intended to broaden the availability and use of NGS-based IVD kits, including companion diagnostics, for patient management.The agreement grants QIAGEN non-exclusive rights to develop and globally commercialize IVD kits to be used together with Illumina’s MiSeq™ Dx and NextSeq™ 550Dx Systems. The agreement also includes rights for expansion of the partnership on future Illumina diagnostic (Dx) systems. Both partners are also exploring opportunities for QIAGEN to develop and market companion diagnostics based on Illumina’s TruSight Oncology (TSO) assays that enable comprehensive genomic profiling of tumor samples in immunotherapy.Illumina and QIAGEN will cooperate to commercialize a menu of c
Show less
Read more
Impact Snapshot
Event Time:
ILMN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ILMN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ILMN alerts
High impacting Illumina, Inc. news events
Weekly update
A roundup of the hottest topics
ILMN
News
- Preimplantation Genetic Testing Market Set to Reach $1.2 Billion by 2031, Driven by Advances in Genetic Screening and Growing IVF Demand: Market Research Intellect [Yahoo! Finance]Yahoo! Finance
- Illumina announces expansion of TruSight Oncology portfolio [Yahoo! Finance]Yahoo! Finance
- Illumina announces expansion of TruSight Oncology portfolioPR Newswire
- INITIATE Ventures Closes $45 Million to Fund and Co-create Companies at the Intersection of Healthcare, Life Sciences, and TechPR Web
- Illumina, Inc. (NASDAQ: ILMN) had its price target raised by analysts at Stephens from $170.00 to $184.00. They now have an "overweight" rating on the stock.MarketBeat
ILMN
Earnings
- 11/4/24 - Beat
ILMN
Sec Filings
- 11/12/24 - Form SC
- 11/7/24 - Form 4
- 11/7/24 - Form 4
- ILMN's page on the SEC website